Behenic acid is a very-long-chain saturated fatty acid found mainly in fixed oils such as moringa and in skin-lipid or emulsion research rather than in classic volatile essential-oil fractions. The current evidence base is strongest for identity, occurrence in fixed-oil profiles, and formulation or barrier-related studies showing occlusive and water-holding effects in lipid systems. Human and animal studies also exist in metabolic contexts, but those findings should be framed carefully because they do not justify topical or medical claims for the isolated constituent.
Chemical identity and composition
PubChem resolves behenic acid under the parent name docosanoic acid, CID 8215, with formula C22H44O2 and IUPAC name docosanoic acid. In the archive, moringa oil already cites behenic acid at 3.0-10.0%, and a camellia seed oil record cites about 1%, supporting its role as a minor-to-moderate fixed-oil marker rather than a volatile aroma driver.
Aroma and practical use
- Use the recorded faint, fatty, waxy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2017 cosmetic-science paper reported that adding behenic acid to phospholipid-structured emulsions increased barrier characteristics, improved acyl-chain ordering, and produced features associated with orthorhombic stratum-corneum-like structure.
A 2017 cosmetic-science paper reported that adding behenic acid to phospholipid-structured emulsions increased barrier characteristics, improved acyl-chain ordering, and produced features associated with orthorhombic stratum-corneum-like structure.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2026 human skin-barrier study reported that a cream containing behenic acid had the best water-holding capacity, significantly increased occlusion, and accelerated transepidermal water-loss recovery in SDS-damaged skin compared with non-treated skin.
A 2026 human skin-barrier study reported that a cream containing behenic acid had the best water-holding capacity, significantly increased occlusion, and accelerated transepidermal water-loss recovery in SDS-damaged skin compared with non-treated skin.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A 2001 randomized crossover metabolic-ward study in mildly hypercholesterolemic men found that behenate oil produced total and LDL cholesterol values not significantly different from palm oil and higher than high-oleic sunflower oil.
A 2001 randomized crossover metabolic-ward study in mildly hypercholesterolemic men found that behenate oil produced total and LDL cholesterol values not significantly different from palm oil and higher than high-oleic sunflower oil.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A 2024 iScience mouse study reported that behenic acid improved abnormal glucose metabolism and birth outcomes in a gestational-diabetes model while reducing inflammatory signaling through the TLR4/NF-kB pathway.
A 2024 iScience mouse study reported that behenic acid improved abnormal glucose metabolism and birth outcomes in a gestational-diabetes model while reducing inflammatory signaling through the TLR4/NF-kB pathway.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
PubChem surfaces Cosmetic Ingredient Review status indicating docosanoic acid is considered safe for use in cosmetics with qualifications, but no fragrance-style IFRA dermal cap was verified for isolated behenic acid.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The human dietary trial found LDL-cholesterol-raising effects in a nutritional context, which is relevant to metabolic interpretation but should not be overextended to topical cosmetic use.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
Most benefit-oriented barrier data come from creams, emulsions, or mixed lipid systems rather than neat isolated behenic acid, so archive copy should stay formulation-contextual.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
occlusive lipid packing
Barrier-oriented formulation studies report that behenic acid can increase occlusive character, improve acyl-chain ordering, and support thicker lamellar structures or cubic lipid packing associated with lower water loss.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
tlr4 nfkb signal modulation in mice
A 2024 gestational-diabetes mouse paper proposed that behenic acid reduced inflammation and insulin resistance by inhibiting TLR4/NF-kB signaling, but that mechanism remains preclinical and not skin-specific.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Most topical evidence involves mixed creams or barrier-lipid systems rather than neat behenic acid alone.
- The broader metabolic literature is mixed and context-dependent, so general wellness claims would overstate the evidence.
- Behenic acid has no dedicated IFRA Standard because it is not a listed fragrance-restricted material (confirmed against the IFRA Standards Index, 51st Amendment, 2026-07-13); no numeric IFRA/Tisserand dermal cap exists to verify, and no constituent-specific sensitization or phototoxicity assessment was located, so sensitizing remains unverified (null).
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.